In Section C, members will get ABBV-744 and oral navitoclax. In Section D, members will acquire ABBV-744 and ruxolitinib. Participants will receive treatment until illness progression or even the participants are unable to tolerate the study drugs. General, our present-day work highlights the potential utilization of ARV-825 in combination with https://brd4-targeted-therapy-abb69024.blogdun.com/32536419/what-does-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-mean